NCT05049083Unknown1 期
A Single-centre, Single-dose, Random, Open, Two-period, Cross-over Relative Bioavailability Study of Different Processes of SHR2554 Tablets in Healthy Adult Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 28
- 试验地点
- 1
- 主要终点
- Vz/F
研究概览
简要总结
TThe study is being conducted to evaluate the relative bioavailability, pharmacokinetics and safety of different tablet processes of SHR2554 in healthy adult subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Provision of written informed consent and willing and able to participate this research.
- •Health female or male aged 18 to 45 at date of informed consent.
- •Weighing ≥45 kg for female and ≥50 kg for male, body mass index between 19.0 and 26.0 kg/m
- •Normal or abnormal but with no clinically significant in physical examination, vital signs, laboratory tests (haematology, clinical chemistry, urinalysis, coagulation function), 12 lead ECG, abdominal B ultrasound and CT.
- •Participants should have no fertility plan and take effective contraceptive measures voluntarily from 2 weeks prior dose (for female) until 3 months after the last dose (for both female and male), and have no sperm or ovum donation plan; for fertile women the serum HCG test must be negative within Screening.
排除标准
- •Participants with chronic or serious disease history or current disease in respiratory system, circulatory system, digestive system, urinary system, blood system, endocrine system, immune system, nervous system, mental system, etc., and are not suitable for enrollment as assessed by the investigator.
- •Surgery history that may affect drug absorption in gastrointestinal tract (including gastrectomy, enterectomy, stomach reduction surgery, etc.).
- •Surgery history within 6 months prior to screening or surgery plans during the study.
- •Plasma donation or blood loss greater than 400 mL or transfusion within 3 months prior to screening, or greater than 200 mL within 1 month prior to screening.
- •Positive results on screening tests for HBsAg and/or HCsAg and/or HIV and/or syphilis.
- •History of drug abuse or positive results of drug tests.
- •Alcohol abuse or smokers (≥14 units of alcohol per week within 6 months prior to screening: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine; ≥5 cigarettes per day), or unable to stop drinking or smoking during the study; positive results on screening tests for alcohol or nicotine.
- •History of allergy/hypersensitivity (allergy/hypersensitivity to more than two substances), or are not suitable for enrollment as assessed by the investigator.
- •Swallowing resistance or obstacles that affect drug absorption.
- •Participation in any other clinical study that included drug treatment within 3 months prior to first SHR2554 dose.
- •Administration of any CYP3A4 inducers or inhibitors within 4 weeks prior to first SHR2554 dose.
- •Administration of any prescription/non-prescription medicine or traditional Chinese medicine or dietary supplement within 2 weeks prior to first SHR2554 dose.
- •Administration of food or drinks that containing grapefruit, methylxanthine or alcohol within 72 hours prior to first SHR2554 dose; Strenuous exercise.
- •Participants who have special dietary requirements and cannot accept a unified diet.
- •Any factors that affect drug absorption, distribution, metabolism or excretion.
- •Lactating women.
- •History of fainting needles or blood; difficulty in blood collection or intolerance of venipuncture blood collection.
- •Any factors are not suitable for enrollment as assessed by the investigator or participants withdrew from the study for their own reasons.
研究组 & 干预措施
Treatment group A
Experimental
干预措施: New Process SHR2554 tablet、Former Process SHR2554 tablet (Drug)
Treatment group B
Experimental
干预措施: Former Process SHR2554 tablet、New Process SHR2554 tablet (Drug)
结局指标
主要结局
Vz/F
时间窗: day 1 to day 11
AUC0-t
时间窗: day 1 to day 11
Cmax
时间窗: day 1 to day 11
AUC0-∞
时间窗: day 1 to day 11
Tmax
时间窗: day 1 to day 11
t1/2
时间窗: day 1 to day 11
CL/F
时间窗: day 1 to day 11
次要结局
- The incidence and severity of adverse events/serious adverse events(from ICF signing date to approximate day 15)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult ParticipantsHealthyNCT02984852Janssen Scientific Affairs, LLC30
终止
1 期
Study to Compare the Pharmacokinetics, Safety and Tolerability of the Pediatric and Adult Branaplam Formulation in Healthy Adults and the Effect of Food on the Latter.Healthy VolunteersNCT05330286Novartis Pharmaceuticals9
已完成
1 期
Study to Assess the Bioavailability, Pharmacokinetics, Safety, and Tolerability of AVP-923 in Healthy Adult ParticipantsHealthy Adult Male and Female VolunteersNCT03381664Avanir Pharmaceuticals17
已完成
1 期
A Study to Assess the Absolute Bioavailability and Pharmacokinetics of Simeprevir (TMC435) Administered as Single Oral Doses of TMC435 and an Intravenous Microdose of [3H]-TMC435 in Healthy Male PatientsHealthy Male ParticipantsNCT01707342Janssen R&D Ireland6
已完成
1 期
A Single Oral Dose Study of ASP015K in Healthy Volunteers Assessing the Relative Bioavailability Across Three Tablet Strengths From a New Formulation of ASP015KBioavailability of ASP015KPharmacokinetics of ASP015KHealthy SubjectsNCT01486017Astellas Pharma Inc30